Printer Friendly

DEPRENYL RESEARCH PROCEEDS ON SCHEDULE WITH BONE HEALTH WARRANTS

 DEPRENYL RESEARCH PROCEEDS ON SCHEDULE WITH BONE HEALTH WARRANTS
 TORONTO, July 21 /PRNewswire/ -- Deprenyl Research Limited (NASDAQ: DEPLF; Toronto) and the Toronto Stock Exchange today announced that they have reached an agreement to proceed on schedule with the record date for the dividend to shareholders of Deprenyl Research Limited payable in warrants of Bone Health Inc. The distribution is subject to clearance of the prospectus qualifying the warrants in Canada and the United States. The record date for the dividend, as previously announced will be July 30, 1992 and the common shares of Deprenyl Research Limited will commence trading on an ex-dividend basis on July 24, 1992. The payment date will be the date that clearance has been received from both Canada and the United States, whichever is later. It was agreed that the warrants will be transferable from the date of their distribution.
 The dividend and the warrants comply with the requirement of the Toronto Stock Exchange.
 -0- 7/21/92
 /CONTACT: Martin Barkin, president of Deprenyl Research, 416-537-4372, or fax, 416-537-1653, or Ralph Shay of the Toronto Stock Exchange, 416-947-4530, or fax, 416-947-4547/
 (DEPLF) CO: Deprenyl Research Limited ST: Ontario IN: MTC SU:


TS-SM -- NY023 -- 1178 07/21/92 09:51 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 21, 1992
Words:204
Previous Article:TPI ENTERPRISES ANNOUNCES 97 PERCENT OF 14-1/4 PERCENT NOTES TENDERED
Next Article:ACC CORP. REPORTS STRONG SECOND QUARTER EARNINGS AND RECORD REVENUES
Topics:


Related Articles
CANGUARD HEALTH TECHNOLOGIES ANNOUNCES LAWSUIT UPDATE
DEPRENYL ADJOURNS APPLICATION FOR INJUNCTION
DEPRENYL RESEARCH ANNOUNCES FINAL PROSPECTUS OF BONE HEALTH INC.
BONE HEALTH INC. & DEPRENYL RESEARCH LIMITED ANNOUNCE SMITHKLINE BEECHAM HAS TRANSFERRED BACK TO LUNAR CORP. ALL ITS RIGHTS TO ONE-ALPHA D-2
DEPRENYL USA ANNOUNCES NO CHANGE AT COMPANY TO ACCOUNT FOR SHARE PRICE PRESSURE
DEPRENYL RESEARCH LTD. & BONE HEALTH INC. TO AWAIT FULL ANALYSIS OF CLINICAL TRIALS BEFORE ISSUING FINAL AMENDMENTS TO PROSPECTUS
LUNAR ANNOUNCES THAT ONE-ALPHA D2 WAS EFFECTIVE
DEPRENYL RESEARCH LTD. RECEIVES NOTIFICATION FROM LUNAR OF TAKEDA'S INTENT TO TERMINATE LICENSE AGREEMENT
BONE HEALTH INC. WARRANTS EXTENDED TO SEPT. 30, 1993
DEPRENYL RESEARCH REPORTS EARNINGS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters